Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age: ≥ 70 years inclusive at Visit 1.~* patients with a confirmed diagnosis of T2DM~* HbA1c of ≥ 7% and ≤10.0% by central laboratory at Visit 1 and assessed by the investigator to be inadequately controlled~* body mass index (BMI) in the range of 19-45kg/m2~Exclusion Criteria:~* FPG ≥ 270 mg/dL (≥ 15.0 mmol/L)~* previous or current participation in any vildagliptin clinical study.~* history of hypersensitivity to DPP-4 inhibitors.~* concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.~* donation of blood or significant blood loss equaling to at least one unit of blood within the past 2 weeks of start of study or a blood transfusion within the past 12 weeks or planned regular transfusions during the study period Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vildagliptin (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).